FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2624659532> ?p ?o ?g. }

• W2624659532 endingPage "1000" @default.
• W2624659532 startingPage "1000" @default.
• W2624659532 abstract "1000 Background: Abemaciclib, an oral, selective inhibitor of CDK4 & 6, dosed on a continuous schedule, demonstrated clinical activity as monotherapy in patients (pts) with treatment refractory hormone receptor positive (HR+) metastatic breast cancer (MBC). The tolerability and activity of abemaciclib + fulvestrant (F) supported Phase 3 evaluation. Methods: MONARCH 2 is a double-blind Phase 3 trial of abemaciclib + F vs placebo (P) + F in women with HR+/HER2- advanced breast cancer. Women who progressed on (neo)adjuvant endocrine therapy (ET), ≤12 months from end of adjuvant ET, or on first line ET for MBC and who had not received chemotherapy for metastatic disease were eligible. Pts were randomized 2:1 to receive abemaciclib at 150 mg Q12H (or 200 mg prior to amendment) or P plus F (500 mg, per label) and stratified by metastatic site (visceral, bone only, or other) and resistance to prior ET (primary vs secondary). Pre/perimenopausal pts received a gonadotropin-releasing hormone agonist. The primary objective was investigator-assessed progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and other efficacy and safety endpoints. Assuming a hazard ratio (HR) of 0.703 in favor of abemaciclib + F, 378 events were needed for 90% power at one sided α=.025. Results: 669 pts were randomized to abemaciclib + F (N=446) and to P + F (N=223). 56% of pts had visceral disease, 72% had measurable disease, 25% had primary ET resistance, and 82% were postmenopausal. In the ITT population 379 PFS events were observed with a median PFS of 16.4 m for abemaciclib + F and 9.3 m for P + F (HR: 0.553; 95% CI: 0.449, 0.681, P<.0000001 by log-rank test). In pts with measurable disease, the ORR was 48.1% (3.5% complete response [CR]) for abemaciclib + F and 21.3% (0% CR) for P + F. The most frequent treatment emergent adverse events for abemaciclib + F vs P + F were diarrhea (86.4% vs 24.7%), neutropenia (46.0% vs 4.0%), nausea (45.1% vs 22.9%), and fatigue (39.9% vs 26.9%). Conclusions: Abemaciclib + fulvestrant was an effective treatment in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy with significantly improved PFS and ORR. Clinical trial information: NCT02107703." @default.
• W2624659532 created "2017-06-15" @default.
• W2624659532 creator A5005424988 @default.
• W2624659532 creator A5007579054 @default.
• W2624659532 creator A5010399021 @default.
• W2624659532 creator A5013148496 @default.
• W2624659532 creator A5014192243 @default.
• W2624659532 creator A5015712277 @default.
• W2624659532 creator A5017506744 @default.
• W2624659532 creator A5023920700 @default.
• W2624659532 creator A5033578877 @default.
• W2624659532 creator A5040919295 @default.
• W2624659532 creator A5044903892 @default.
• W2624659532 creator A5059156506 @default.
• W2624659532 creator A5066769011 @default.
• W2624659532 creator A5067189124 @default.
• W2624659532 creator A5069176422 @default.
• W2624659532 creator A5073900195 @default.
• W2624659532 creator A5091087439 @default.
• W2624659532 creator A5091245889 @default.
• W2624659532 date "2017-05-20" @default.
• W2624659532 modified "2023-10-18" @default.
• W2624659532 title "MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy" @default.
• W2624659532 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.1000" @default.
• W2624659532 hasPublicationYear "2017" @default.
• W2624659532 type Work @default.
• W2624659532 sameAs 2624659532 @default.
• W2624659532 citedByCount "10" @default.
• W2624659532 countsByYear W26246595322017 @default.
• W2624659532 countsByYear W26246595322018 @default.
• W2624659532 countsByYear W26246595322021 @default.
• W2624659532 countsByYear W26246595322022 @default.
• W2624659532 countsByYear W26246595322023 @default.
• W2624659532 crossrefType "journal-article" @default.
• W2624659532 hasAuthorship W2624659532A5005424988 @default.
• W2624659532 hasAuthorship W2624659532A5007579054 @default.
• W2624659532 hasAuthorship W2624659532A5010399021 @default.
• W2624659532 hasAuthorship W2624659532A5013148496 @default.
• W2624659532 hasAuthorship W2624659532A5014192243 @default.
• W2624659532 hasAuthorship W2624659532A5015712277 @default.
• W2624659532 hasAuthorship W2624659532A5017506744 @default.
• W2624659532 hasAuthorship W2624659532A5023920700 @default.
• W2624659532 hasAuthorship W2624659532A5033578877 @default.
• W2624659532 hasAuthorship W2624659532A5040919295 @default.
• W2624659532 hasAuthorship W2624659532A5044903892 @default.
• W2624659532 hasAuthorship W2624659532A5059156506 @default.
• W2624659532 hasAuthorship W2624659532A5066769011 @default.
• W2624659532 hasAuthorship W2624659532A5067189124 @default.
• W2624659532 hasAuthorship W2624659532A5069176422 @default.
• W2624659532 hasAuthorship W2624659532A5073900195 @default.
• W2624659532 hasAuthorship W2624659532A5091087439 @default.
• W2624659532 hasAuthorship W2624659532A5091245889 @default.
• W2624659532 hasConcept C121608353 @default.
• W2624659532 hasConcept C126322002 @default.
• W2624659532 hasConcept C143998085 @default.
• W2624659532 hasConcept C168563851 @default.
• W2624659532 hasConcept C197934379 @default.
• W2624659532 hasConcept C203092338 @default.
• W2624659532 hasConcept C207103383 @default.
• W2624659532 hasConcept C2775930923 @default.
• W2624659532 hasConcept C2777176818 @default.
• W2624659532 hasConcept C2778375690 @default.
• W2624659532 hasConcept C2780482068 @default.
• W2624659532 hasConcept C2908647359 @default.
• W2624659532 hasConcept C44249647 @default.
• W2624659532 hasConcept C530470458 @default.
• W2624659532 hasConcept C71924100 @default.
• W2624659532 hasConcept C90924648 @default.
• W2624659532 hasConcept C99454951 @default.
• W2624659532 hasConceptScore W2624659532C121608353 @default.
• W2624659532 hasConceptScore W2624659532C126322002 @default.
• W2624659532 hasConceptScore W2624659532C143998085 @default.
• W2624659532 hasConceptScore W2624659532C168563851 @default.
• W2624659532 hasConceptScore W2624659532C197934379 @default.
• W2624659532 hasConceptScore W2624659532C203092338 @default.
• W2624659532 hasConceptScore W2624659532C207103383 @default.
• W2624659532 hasConceptScore W2624659532C2775930923 @default.
• W2624659532 hasConceptScore W2624659532C2777176818 @default.
• W2624659532 hasConceptScore W2624659532C2778375690 @default.
• W2624659532 hasConceptScore W2624659532C2780482068 @default.
• W2624659532 hasConceptScore W2624659532C2908647359 @default.
• W2624659532 hasConceptScore W2624659532C44249647 @default.
• W2624659532 hasConceptScore W2624659532C530470458 @default.
• W2624659532 hasConceptScore W2624659532C71924100 @default.
• W2624659532 hasConceptScore W2624659532C90924648 @default.
• W2624659532 hasConceptScore W2624659532C99454951 @default.
• W2624659532 hasIssue "15_suppl" @default.
• W2624659532 hasLocation W26246595321 @default.
• W2624659532 hasOpenAccess W2624659532 @default.
• W2624659532 hasPrimaryLocation W26246595321 @default.
• W2624659532 hasRelatedWork W1871851646 @default.
• W2624659532 hasRelatedWork W1984009715 @default.
• W2624659532 hasRelatedWork W2134047754 @default.
• W2624659532 hasRelatedWork W2294069589 @default.
• W2624659532 hasRelatedWork W2593892593 @default.
• W2624659532 hasRelatedWork W2941264805 @default.
• W2624659532 hasRelatedWork W2970181139 @default.
• W2624659532 hasRelatedWork W4220872882 @default.

• next